Trade Mark Journal No.2025/040 3 October 2025
WO0000001876417 (5,40)
Office of origin: United States of America
Date of International Registration:29 July 2025
Date of designation in the UK:
29 July 2025
The mark consists of the stylized wording RINGTX.
International priority date claimed: 29 January 2025
(United States of America)
(99022541)
- Class 5
- Encapsulated nucleic acids for use as biological therapeutics in gene therapy for the treatment of human diseases and disorders; pharmaceutical preparations for use in gene therapy for the treatment of rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases.
- Class 40
- Custom manufacture of anelloviruses.
Ring Therapeutics, Inc.
Representative: Christina M. Licursi Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston MA 02210-2206, UNITED STATES OF AMERICA